Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Gene Mutation Reduces Glucose Uptake and Premature Mortality

By LabMedica International staff writers
Posted on 25 Oct 2018
A loss-of-function mutation in a gene in the digestive tract reduces glucose uptake from ingested food, which helps to protect the individual from diabetes, obesity, heart failure, and premature mortality from these disorders.

Loss-of-function mutations in the SGLT1 (sodium/glucose co-transporter-1) gene result in a rare glucose/galactose malabsorption disorder and neonatal death if untreated. More...
In the general population, effects related to intestinal glucose absorption have not been well characterized.

To shed light on these effects, investigators at Harvard University Medical School (Boston, MA, USA) conducted experiments designed to identify functional SGLT1 gene variants and characterize their clinical consequences.

Whole exome sequencing was performed on 8,478 participants in the ARIC (Atherosclerosis Risk in Communities) study. This study was a 25-year-long observational trial of atherosclerosis and cardiovascular risk factors in people living in four communities in the USA. In addition to genetic testing, the association of functional, nonsynonymous substitutions in SGLT1 with two-hour oral glucose tolerance test results was determined.

Results published in the October 9, 2018, issue of the Journal of the American College of Cardiology revealed that approximately 6% of the ARIC participants carried a mutation in SGLT-1 that caused limited impairment of glucose absorption. Individuals with this mutation had a lower incidence of type II diabetes, were less obese, had a lower incidence of heart failure, and had a lower mortality rate when compared to those without the mutation.

The investigators believe that reduced intestinal glucose uptake induced by the mutation may protect the individual from long-term cardiovascular and metabolic disorders, providing support for development of therapies that will target SGLT1 function to prevent and treat metabolic conditions.

"We are excited about this study because it helps clarify the link between what we eat, what we absorb, and our risk for disease. Knowing this opens the door to improved therapies for cardio-metabolic disease," said senior author Dr. Scott D. Solomon, professor of medicine at Harvard University Medical School. "This study is the first to fully evaluate the link between mutations in the gene mainly responsible for absorbing glucose in the gut--SGLT-1, or sodium glucose co-transporter-1--and cardio-metabolic disease."

Related Links:
Harvard University Medical School


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Gold Member
Connectivity Solution
EKF Link
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image

Labcorp Partners With Grupo Fleury to Expand Clinical Trial Operations in Brazil

Multinational clinical trials require laboratory partners that combine global expertise with local operational capabilities. Brazil is an important clinical research destination, supported by its diverse... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.